VBIO Valion Bio, Inc.
Financings ·
Valion Bio sold 4,717.73 Series C preferred shares for $4,717,717.61, but $3,217,717.61 of that stays with the buyers to cover overdue cash true-up payments. The company receives $1,500,000 in cash.
Valion's CDMO unit finished an initial evaluation of LarmorBio's BioScan-NMR platform for continuous bioprocess monitoring.
Valion Bio filed a $100,000,000 shelf registration on October 7, 2026, and the same day agreed to sell 3i $50,000 of Series B preferred and warrants. The public float used for the shelf was based on a $7.75 price, while the last reported sale on October 5 was $2.48.
Valion and Shear Kershman Laboratories finished formulation work on a needle-free Entolimod, with systemic exposure testing next.
Board member Dean Zikria becomes interim chief executive officer, Thomas Jensen takes the board chair, and Lisa Wolf keeps her roles.
The split takes effect August 31, 2026 under the same VBIO symbol, and the company says it aims to meet the Nasdaq minimum bid price rule.
Tivic Health Systems bought the manufacturing and development assets of Scorpius Holdings at a public auction, paying $16,253,147.10 in cash funded by a senior secured convertible note sold to 3i. The note converts at a fixed price and at a discount to market, which can add shares.
Tivic reported $669,000 of cash at March 31, 2025 and a $1.5 million net loss for the quarter. It then lined up a $25 million equity line and a purchase agreement for up to $8.4 million of securities.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $780,000 | |
| Research and development | $3.1 million | $1.3 million |
| Net income (loss) | -$8.9 million | -$5.7 million |
| Cash from operations | -$7.0 million | -$5.7 million |
| Cash and equivalents | $12.6 million | $2.0 million |
Our latest story on this, dated Aug 27, 2026: "Valion sets 1-for-25 reverse stock split to regain Nasdaq compliance". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 8, 2026: "Valion Bio files $100,000,000 shelf with $5,000,000 at-the-market program". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Dec 11, 2025: "Tivic Health Systems (now Valion Bio) buys Scorpius CDMO assets for $16,253,147.10". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 27, 2026: "Valion Bio sells preferred stock, mostly to settle overdue Series C payments". The story links the filing or release it is based on. Read the story.
Valion Bio, Inc. trades under the ticker VBIO on NASDAQ.
Valion Bio, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Valion Bio, Inc. is 1787740. Its filings are on SEC EDGAR.
22,189,739 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Valion Bio, Inc. under United States.
Our directory classifies Valion Bio, Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Valion Bio, Inc. is US9189422028.
aibio.space lists Valion Bio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Valion Bio, Inc. reported a net loss of $8.9 million for the fiscal year ended Dec 31, 2025, and used $7.0 million of cash in operations, per its annual report to the SEC.
$3.1 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported a financing. SEC Form S-3. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.02,7.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,5.02,5.07,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01). Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,8.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,1.02,2.01,2.03,3.02,3.03,5.03,7.01,9.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,2.05,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 2.02,7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,3.03,5.03,9.01). Source
Reported a financing. SEC Form 8-K (Items 8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,8.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,8.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,2.02,3.02,7.01,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,7.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,5.03,7.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio